New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 14, 2013
10:55 EDTNBS, NBS, ONVO, ONVO, LIFE, LIFE, GSK, GSK, CELG, CELG, BAX, BAX, STEM, STEM, OSIR, OSIR, BLUE, BLUE, SGMO, SGMO, FCSC, FCSC, PSTI, PSTI, MBLTY, MBLTY, ATHX, ATHX, BTX, BTXAlliance for Regenerative Medicine to hold a meeting
2013 Stem Cell Meeting on the Mesa is being held in La Jolla, California on October 14-16 with webcasted presentations to begin on October 14 at 11 am; not all presentations may be webcasted. Webcast Link
News For NBS;ATHX;MBLTY;PSTI;FCSC;SGMO;BLUE;OSIR;STEM;BAX;CELG;GSK;LIFE;ONVO;BTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
May 13, 2015
08:04 EDTBTXBioTime unit awarded $1.6M grand from Israel's OCS
BioTime and its subsidiary Cell Cure Neurosciences announced that Cell Cure has been awarded a grant for 2015 of approximately $1.61M from Israel’s Office of the Chief Scientist to help finance the development of OpRegen, a cell-based therapeutic product that consists of animal product-free retinal pigment epithelial cells with high purity and potency. Cell Cure is now enrolling patients at Hadassah University Medical Center in Jerusalem, Israel, in a clinical Phase I/IIa dose-escalation study evaluating the safety and efficacy of OpRegen for geographic atrophy, the severe stage of the dry form of age-related macular degeneration. The Phase I/IIa clinical trial was opened in February 2015 following regulatory clearance from the U.S. FDA and the Israeli Ministry of Health. The trial consists of four cohorts and will evaluate three different dose regimens. Cell Cure expects to report interim data from the cohorts in the coming months.
07:07 EDTGSKGSK, Emergent BioSolutions, Oxford initiate Prime Boost study of Ebola vaccine
A new phase 1 study has begun at the University of Oxford that will investigate the use of a modified vaccinia Ankara, or MVA, Ebola Zaire vaccine candidate, or MVA EBOZ, as a prime-boost to GlaxoSmithKline's (GSK) Chimp Adenovirus type 3, or ChAd3, Ebola vaccine candidate. The study, being conducted by the clinical research group of Professor Adrian Hill of the Jenner Institute, has received regulatory approval to begin from the United Kingdom's Medicines and Healthcare Products Regulatory Agency, or MHRA. The phase 1 study has a planned enrollment of 38 volunteers of which 6 will receive MVA EBOZ only while the other 32 will receive ChAd3-EBO-Z prime followed by MVA EBOZ boost. Emergent BioSolutions (EBS) manufactured the supply of MVA EBOZ to be used in this phase 1 study, which is being conducted in the U.K. with support from the Wellcome Trust and the U.K. Department for International Development.
05:43 EDTPSTIPluristem announces PMDA quality approval for PLX-PAD cells for use in trial
Subscribe for More Information
May 12, 2015
17:54 EDTFCSCOn The Fly: After Hours Movers
Subscribe for More Information
16:15 EDTFCSCFibrocell Science receives rare pediatric disease designation for FCX-007
Fibrocell Science announced that the FDA has granted rare pediatric disease designation for Fibrocell's lead orphan gene-therapy drug candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa, or RDEB. The rare pediatric disease designation augments the Orphan Drug designation granted by the FDA and announced by Fibrocell in June 2014 for FCX-007 to treat dystrophic epidermolysis bullosa, or DEB, which includes RDEB.
09:38 EDTBTXBioTime management to meet with Oppenheimer
Meetings to be held in New York on May 14 and in Boston on May 15 hosted by Oppenheimer.
09:02 EDTBAXBaxter expects to establish BioScience business as separate business by mid-year
Subscribe for More Information
09:01 EDTBAXBaxter to acquire Oncaspar product portfolio from Sigma-Tau for $900M
Subscribe for More Information
07:33 EDTCELGAlliqua announces licensing agreement with Celgene
Subscribe for More Information
07:06 EDTBAXKamada sees FY15 revenue $70M-$73M, consensus $78.69M
Kamada (KMDA) sees revenue from its Distributed Product Segment projected to be between $26 million and $28 million and revenue from its Proprietary Products Segment projected to be between $45 million and $47 million. The company notes that revenue projections for 2015 take into account an expected negative foreign exchange impact of approximately $2.0 million in relation to product sales in Israel and Russia, and presume that U.S. revenue from the agreement with Baxter (BAX) remains on track.
06:02 EDTGSKGSK CEO cites 'poor choices' in rivals' M&A deals, Financial Times reports
Subscribe for More Information
05:31 EDTMBLTYMesoblast announces results on cell therapy in rheumatoid arthritis
Subscribe for More Information
May 11, 2015
19:15 EDTATHXOn The Fly: After Hours Movers
Subscribe for More Information
17:36 EDTATHXAthersys down 10.1% after Pfizer notified that it will terminate agreement
Subscribe for More Information
17:34 EDTATHXAthersys receives notification that Pfizer will terminate agreement
Subscribe for More Information
16:27 EDTATHXAthersys reports Q1 EPS (16c), consensus (9c)
Subscribe for More Information
15:54 EDTGSKGlaxo CEO defends strategy, warns of risks of chasing higher prices, FT says
GlaxoSmithKline (GSK) CEO Andrew Witty defends the company's shift in focus from high-priced prescription drugs to higher volume, but lower priced, products, warning that chasing ever-higher prices risks undermining the industry and may create "its own tension that leads to some kind of change,” reported Financial Times, citing an interview. Witty acknowledges the company's asset swap with Novartis (NVS) opens the door to a potential break up, but argues there are benefits to keeping pharmaceuticals, vaccines and consumer goods together and there would be “no logic” in a split at this early time after the Novartis deal, the report added. Reference Link
14:34 EDTBLUEbluebird bio June volatility elevated on sharp rally
bluebird bio May call option implied volatility is at 73, June is at 109, August is at 82; compared to its 90-day average of 86, suggesting large near term price movement.
07:51 EDTBLUEConference should be positive turning point for bluebird bio, says SunTrust
SunTrust expects data due to be released at the EHA conference to create a positive turning point for bluebird bio. The firm notes that the data will include information on a sickle cell patient treated with bluebird's LentiGlobin, and the firm thinks that LentiGlobin is an effective sickle cell treatment. The firm now includes sickle cell in its estimates for the company and raised its price target on the shares to $205 from $115. It keeps a Buy rating o nthe stock.
05:58 EDTGSKUNC, GlaxoSmithKline create dedicated HIV Cure center
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use